Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 CroíValve Grabs IDE OK for TANDEM II Early Feasibility Trial - Medical Product Outsourcing
OEM News

CroíValve Grabs IDE OK for TANDEM II Early Feasibility Trial

The trial will assess the DUO tricuspid coaptation valve system for tricuspid regurgitation.

CroíValve, an Irish-U.S. based company with a novel transcatheter solution for tricuspid regurgitation, has begun its TANDEM II early feasibility study (EFS) for the DUO tricuspid coaptation valve system. This follows U.S. Food and Drug Administration (FDA) investigational device exemption (IDE) and CMS approval.
 
DUO is comprised of a coaptation valve that works with the native tricuspid valve to restore function. It’s delivered via a percutaneous approach and secured by a novel anchor system to leave the right heart and native valve apparatus untouched, according to the company.
 
Europe’s first-in-human TANDEM I trial demonstrated strong symptomatic improvement among a pool of highly symptomatic tricuspid regurgitation (TR) patients with a broad range of anatomies. CroíValve said those cases also showed the procedure is quick to learn and perform, and doesn’t need complex imaging.
 
The TANDEM II prospective, multi-center, non-randomized single-arm trial will assess DUO’s safety and performance for severe or greater symptomatic TR.
 
“We are delighted to initiate TANDEM II, with strong interest in participation in the study from leading U.S. centers. This marks a significant step forward in our efforts to continue generating clinical evidence demonstrating the safety and effectiveness of DUO,” said CroíValve CEO Lucy O’Keeffe. “We are confident it has the potential to revolutionize the standard of care by redefining how TR is treated, and ultimately enhancing the lives of patients in need.”

Add us as a preferred source on Google

Get the latest Medical Product Outsourcing news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters